# Viral Specific T-Lymphocytes to Treat Adenovirus or CMV

> **NCT04364178** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Jessie L. Alexander** · enrollment: 25 (estimated)

## Conditions studied

- Adenovirus
- Cytomegalovirus Infections

## Interventions

- **BIOLOGICAL:** Adenovirus Specific T- Lymphocytes
- **BIOLOGICAL:** Cytomegalovirus Specific T-Lymphocytes

## Key facts

- **NCT ID:** NCT04364178
- **Lead sponsor:** Jessie L. Alexander
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2020-08-12
- **Primary completion:** 2029-04-01
- **Final completion:** 2032-01-01
- **Target enrollment:** 25 (ESTIMATED)
- **Last updated:** 2024-05-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04364178

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04364178, "Viral Specific T-Lymphocytes to Treat Adenovirus or CMV". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04364178. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*